The Myeloma Patient Outcome Scale is the first quality of life tool developed for clinical use and validated in patients with follicular lymphoma

TY - JOUR

T1 - The Myeloma Patient Outcome Scale is the first quality of life tool developed for clinical use and validated in patients with follicular lymphoma

AU - Davies, Joanna M

AU - Osborne, Thomas R

AU - Edmonds, Polly M

AU - Schey, Steve A

AU - Devereux, Steve

AU - Higginson, Irene J

AU - Ramsenthaler, Christina

N1 - This article is protected by copyright. All rights reserved.

PY - 2017/3/9

Y1 - 2017/3/9

N2 - OBJECTIVES: The development of novel agents and an ageing population has led to an increasing number of patients with follicular lymphoma (FL) living longer with disease. Health-related quality of life (HRQOL) is a priority for patients and should guide clinical decisions. The Myeloma Patient Outcome Scale (MyPOS), originally developed for myeloma, was validated in a cross-sectional survey recruiting 124 FL patients.METHODS: Content and construct validity, structural validity using confirmatory factor analyses, reliability and acceptability were evaluated.RESULTS: Three subscales were indicated: symptoms and function, emotional response, and healthcare support. MyPOS symptom and function scores were higher (worse) in participants with poorer ECOG performance status (F=26.2, p<.000) and discriminated between patients on and off treatment. Good convergent and discriminant validity in comparison to the EORTC-QLQ-C30 and FACT-Lym were demonstrated. Internal consistency was good; α coefficient 0.70-0.95 for the total MyPOS score and subscales.CONCLUSION: The MyPOS is valid, reliable and acceptable, and can be used to support clinical care of FL patients. This is the first measurement tool developed specially for use in clinical practice that has been validated for use in people with FL. Further longitudinal validation is now required to support its use in outcome measurement.

AB - OBJECTIVES: The development of novel agents and an ageing population has led to an increasing number of patients with follicular lymphoma (FL) living longer with disease. Health-related quality of life (HRQOL) is a priority for patients and should guide clinical decisions. The Myeloma Patient Outcome Scale (MyPOS), originally developed for myeloma, was validated in a cross-sectional survey recruiting 124 FL patients.METHODS: Content and construct validity, structural validity using confirmatory factor analyses, reliability and acceptability were evaluated.RESULTS: Three subscales were indicated: symptoms and function, emotional response, and healthcare support. MyPOS symptom and function scores were higher (worse) in participants with poorer ECOG performance status (F=26.2, p<.000) and discriminated between patients on and off treatment. Good convergent and discriminant validity in comparison to the EORTC-QLQ-C30 and FACT-Lym were demonstrated. Internal consistency was good; α coefficient 0.70-0.95 for the total MyPOS score and subscales.CONCLUSION: The MyPOS is valid, reliable and acceptable, and can be used to support clinical care of FL patients. This is the first measurement tool developed specially for use in clinical practice that has been validated for use in people with FL. Further longitudinal validation is now required to support its use in outcome measurement.

KW - Factor analysis

KW - Follicular lymphoma

KW - Non-Hodgkin lymphoma

KW - Psychometrics

KW - Quality of life

KW - Questionnaire validation

UR - http://www.scopus.com/inward/record.url?scp=85015075836&partnerID=8YFLogxK

U2 - 10.1111/ejh.12864

DO - 10.1111/ejh.12864

M3 - Article

C2 - 28160316

SN - 0902-4441

VL - 98

SP - 508

EP - 516

JO - European Journal of Haematology

JF - European Journal of Haematology

IS - 5

ER -